louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02288598: Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering
Official title: Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stuttering
Fluency Disorders
Speech Disorders
Keywords: Stammering
Brain stimulation
Lead sponsor: University of Oxford
Sponsor class: OTHER
First posted: 2014-11-11
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to test whether the addition of transcranial direct current stimulation (TDCS) to speech fluency training results in improvements in speech fluency in adults with developmental stuttering. Half of the participants will receive anodal TDCS on five consecutive days, the other half will receive a sham stimulation for the same amount of time.

Detailed description: Studies using TDCS have shown improvements in motor performance, and in expressive language skills in clinical and healthy populations. The benefits of single sessions of TDCS are short-lived. However, stimulation over multiple sessions can increase and prolong learning effects that can persist for several weeks after the end of the stimulation period. We aim to target left hemisphere frontal regions involved in speech production with TDCS, and to pair this stimulation with speech fluency training.

Eligibility criteria: Inclusion Criteria:

* Native speaker of English.
* Right handed.
* Participant has moderate to severe Developmental Stuttering (Stammering)

Exclusion Criteria:

* Speech, language or communication disorder other than Developmental Stuttering.
* Sensory impairment (hearing loss or visual impairment)
* History of drug abuse.
* History of seizures
* History of a neurological or psychiatric illness.
* History of neurosurgical procedure.
* Currently taking certain prescription medications such as anti-depressants and anti-malarial medication (as these may lower the seizure threshold)

Primary outcomes:
measure: Change from baseline proportion of stuttering in speech sample
timeFrame: 1 week post-treatment
measure: Change from baseline proportion of stuttering in speech sample
timeFrame: 6 weeks post-treatment
Secondary outcomes:
measure: Change from baseline on the Stuttering Severity Instrument version 4 (SSI-4)
timeFrame: 1 week post-treatment
measure: Change from baseline on the Stuttering Severity Instrument version 4 (SSI-4)
timeFrame: 6 weeks post-treatment
measure: Change from baseline on Overall Assessment of Speaker's Experience of Stuttering (OASES)
timeFrame: 6 weeks post-treatment
Other outcomes:
Locations:
city: Oxford
country: United Kingdom
facility: University of Oxford
Study officials:
affiliation: University of Oxford
name: Kate Watkins, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02558998: Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care
Official title: Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Non-Small Cell Lung Carcinoma (NSCLC)
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2015-09-24
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The objective of this study is to 1) evaluate the impact of a novel individualized care planning/ educational technology (the On Q Care Planning System or CPS) on oncology patient and provider knowledge, attitudes and beliefs about Non-Small Cell Lung Carcinoma (NSCLC) clinical trials, as well as 2) to evaluate the impact of the On Q CPS on patient referral to and enrollment in NSCLC clinical trials.


Eligibility criteria: Inclusion Criteria:

* All participants must be 18 years of age or older.
* Patient participants must have Stage III, IV and/or recurrent NSCLC.
* Patient participants must be at a point of treatment initiation/change or evaluation for treatment initiation/change
* Patients must have working email address and internet access

Exclusion Criteria:

* Any participant who cannot understand written or spoken English.
* Any participant who is not competent to provide informed consent for study participation per the investigator.
* Any participant who cannot be present for the related study visits and/or complete the post-test assessment

Primary outcomes:
measure: Number of patient who completed surveys
timeFrame: 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Joshua Bauml, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02785497: Electrical Stimulation of Cutaneous Lesions
Official title: Electrical Stimulation of Cutaneous Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Ulcer
Burns
Keywords: Electrical stimulation
wound healing
Polarity current
Burn
Chronic ulcer
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2016-05-27
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Skin lesions, such as chronic ulcers and burns, represent a serious public health problem due to high government costs, and scarce successful conservative treatments.There is a growing scientific literature on the use of electrotherapy in the process of wound healing, but in return there is a dearth of scientific studies on the use of various types of currents and the different parameters in the proposed treatments.

Detailed description: This project proposes the use of polarized currents to increase the speed of healing in chronic ulcers and donor sites in burn patients. Will be included 30 patients with chronic ulcers and 30 burn patients undergoing skin graft surgery, will be randomized into control and treated groups. For the ulcer chronic group treatment will be with 50 minutes high voltage and 10 minutes diadynamica current and the burn group only 50 minutes high voltage current.

Eligibility criteria: Inclusion Criteria:

* all patients admitted to the rehabilitation center of Clinical Hospital with chronic ulcer, Faculty of Medicine of Ribeirão Preto / USP, in the period between january 2010 and december 2011
* all patients admitted to the Burns Unit of Clinical Hospital, Faculty of Medicine of Ribeirão Preto / USP, in the period between march 2011 and december 2012

Exclusion Criteria:

* Infection
* weight below 16kg

Primary outcomes:
measure: clinical evaluation of the lesion
timeFrame: Two years
Secondary outcomes:
measure: standard photographic records of the wounds and quantification by digital software
timeFrame: Two years
Other outcomes:
measure: Expert in evaluating healing images for a score
timeFrame: Two years
Locations:
city: Ribeirao Preto
country: Brazil
facility: University of Sao Paulo
state: Sao Paulo
Study officials:
affiliation: University of Sao Paulo
name: Rinaldo Guirro, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01781897: Electroacupuncture for the Treatment of Functional Constipation
Official title: A Randomized Controlled Trial of Acupuncture to Treat Functional Constipation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Functional Constipation
Keywords: acupuncture
electro-acupuncture
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
First posted: 2013-02-01
Enrollment: 243
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effect of electroacupuncture on functional constipation.

Detailed description: This study will supply significant evidence for using acupuncture to treat functional constipation(FC), and will help us to identify whether it is a therapeutic effect rather than a placebo effect.

Eligibility criteria: Inclusion criteria:

* functional constipation according to the Roman Ⅲ standard;
* aged between 18 and 65 years old

Exclusion criteria:

* unconsciousness, psychosis or can't express subjective symptoms;
* pregnant women or women in lactation period;
* serious diseases of the heart, liver, kidney, and others;
* bleeding disorders.

Primary outcomes:
measure: number of defecation per week
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Hospital of Huazhong University of Science and Technology
state: Hubei
city: Wuhan
country: China
facility: Hubei Provincial Hospital of TCM
state: Hubei
city: Wuhan
country: China
facility: Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
affiliation: HUST(Huazhong University of Science and Technology) Hospital
name: Xiaohu Xu, Doctor
role: PRINCIPAL_INVESTIGATOR
affiliation: Hubei Hospital of Traditional Chinese Medicine
name: Feng Hu, Master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00000197: Propranolol for Treatment of Cocaine Addiction - 2
Official title: Propranolol for Treatment of Cocaine Addiction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cocaine-Related Disorders
Keywords: cocaine
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: University of Pennsylvania
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 25
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of propanolol in the early treatment of cocaine dependence.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Side effects
measure: Cocaine use
measure: Cocaine withdrawal
measure: Cocaine craving
measure: Mood and anxiety
measure: Clinical improvement
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Kyle Kampman, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03466697: Role of Dopamine Transporter in Glucose Control
Official title: Role of Dopamine Transporter in Glucose Loading of Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: Pusan National University Hospital
Sponsor class: OTHER
First posted: 2018-03-15
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Healthy subjects will be enrolled in this study. Each subject will be scanned twice with F18-FP-CIT PET which is commercially available. F18-FP-CIT reflects dopamine transporter availability of striatum. Before each PET scan, subject will be injected either glucose or normal saline. Therefore, PET scan will reflect the changes of dopamine transporter availability after the injection of glucose.


Eligibility criteria: Inclusion Criteria:

* healthy subjects

Exclusion Criteria:

* known neurologic disorder
* known drug addiction
* known endocrine disorder

Primary outcomes:
measure: Specific binding ratio of dopamine transporter availabilitiy measured from PET scans
timeFrame: less than 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Pusan National University Hospital
Study officials:
affiliation: Pusan National University Hospital
name: Kyoungjune Pak, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06963697: Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Official title: Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Study type: EXPANDED_ACCESS
Overall status: AVAILABLE
Conditions: Cancer
Lead sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Sponsor class: OTHER
First posted: 2025-05-09
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: This is an intermediate patient expanded access protocol for treatment of patients with local or metastatic solid tumors with a neoantigen synthetic long peptide vaccine.


Eligibility criteria: Patients must satisfy the following criteria to be enrolled in the protocol:

Main Inclusion Criterion:

1. Patient who qualifies for treatment under 21 CFR 312.305 based on treating physician judgment, inability to enroll in study JLF-200, must have received or be ineligible for FDA-approved therapies for their specific cancer type, and an estimated 5-year survival of less than 50%.

Other Inclusion Criteria:

1. \>= 12 years of age.
2. ECOG performance status ≤ 2 or Karnofsky score of \>=70.
3. Adequate organ function allowing favorable benefit to risk ratio per the treating physician
4. Systemic corticosteroid therapy is permitted provided dosing is no greater than 4 mg per day (dexamethasone or equivalent) on the day of vaccine administration.
5. Ability to understand and willingness to sign an IRB approved written informed consent document.

Exclusion Criteria:

1. History of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty or known allergy to a component of the neoantigen synthetic long peptide vaccine.
2. Intercurrent illness requiring chronic use of medications that may interfere with rescue medications for treatment of vaccine-related anaphylaxis or attenuate immune response to vaccine treatment (immunosuppressive therapies).
3. Psychiatric illness or social situations that would limit compliance with study requirements.
4. History of pre-existing immunodeficiency disorder or autoimmune condition requiring immunosuppressive therapy that would preclude response to vaccine. 5. Females of childbearing potential may participate provided they agree to practice abstinence; and, if heterosexually active, agree to use at least 2 highly effective contraceptive methods throughout the study and for 3 months following the last dose of study drug; and have a negative serum pregnancy test.

6. Females of non-childbearing potential must be post-menopausal or have been surgically sterilized.

7. Male subjects with a female partner of childbearing potential must agree to practice abstinence or to use a physician-approved contraceptive method throughout the study and for 3 months following the last dose of study drug.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05737797: Non-Invasive Diagnosis of Endometrial Cancer
Official title: Non-Invasive Diagnosis of Endometrial Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Endometrial Cancer
Keywords: Endometrial cancer
Next-generation sequencing
Screening
Microsatellite instability
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2023-02-21
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The study aims to determine whether next generation sequencing and microsatellite analysis of cervical cytology is sensitive for the detection of endometrial carcinoma.

Detailed description: Definitive diagnosis of endometrial cancer relies on endometrial biopsy, in addition to imaging. Biopsy is however invasive and often painful, and its sensitivity in only moderate. Cervical cytology could be an alternative. This is a proof-of-concept study. The investigators will carry out next generation sequencing of cervical cytology in patients with confirmed endometrial carcinoma, in order to determine whether activating variants are identified. About 15% of endometrial carcinomas are microsatellite instable (MSI). The investigators will therefore also carry out MSI analysis using MSICare in the subset of cases with MMR-deficient cancer.

Eligibility criteria: Inclusion Criteria:

* Endometrial cancer requiring hysterectomy
* Patient covered by French social Security
* Patient capable of giving written informed consent

Exclusion Criteria:

- Chemotherapy

Primary outcomes:
measure: Activating variants and MSI via cytology
timeFrame: 16 months
Secondary outcomes:
measure: Type of variants
timeFrame: 16 months
measure: Number of variants
timeFrame: 16 months
measure: Frequency of variants
timeFrame: 16 months
measure: Comparison with the proportion of variants seen on the pathological
timeFrame: 16 months
measure: Comparison with the proportion of microsatellite instability detected on the pathological specimen.
timeFrame: 16 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Medical genetics department
Study officials:
References:
Clinical trial NCT00802997: Trial Assessing Cooled Radiofrequency Denervation as a Treatment for Sacroiliac Joint Pain Using the Sinergy System
Official title: A Double Blind, Randomized, Controlled Trial Assessing Cooled Radiofrequency Denervation as a Treatment fr Sacroiliac Joint Pain Using the Sinergy System
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Other Acute Pain
Chronic Pain
Lead sponsor: Baylis Medical Company
Sponsor class: INDUSTRY
First posted: 2008-12-05
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: to evaluate the effectiveness of cooled radiotherapy denervation of the sacroiliac region using the sinergy system by comparing a treatment group to a placebo group


Eligibility criteria: Inclusion Criteria:

* Predominantly axial pain below L5 vertebrae
* greater than 75%pain relief from 2 seperate lateral branch blocks done on different days
* chronic axial pain lasting longer than 6 months, 3 day average VAS between 4 and 8
* age greater than 18
* failed to acheive adequate improvemnet with comprehensive non-operative treatments, includingbut not limited to: activity alteration, non0steriodal anti-iflammatory, physical and/or manual therap, and flurpscopically guided steriod injections in and around the area of pathology
* all other possible sources oflow back pain have been ruled out, including but not limited to the intervertebral discs, bone fracture.

Exclusion Criteria:

* Beck Depression greater than 20%
* irreversible psychological barriers to recovery
* spinal pathology that may impede recovery such as spins bifida occulta,
* moderate to severe foraminal or central canal stenosis
* systemic infection or localized infection at inducer site
* concomitant cervical or thoracic pain greater than 2/10 on VAS
* uncontrolled or acute disease
* chronic severe condition such as rheumatoid arthritis
* preganancy
* active radicular pain
* immunosuppression
* workers compensation
* allergy to injectants or medications used in procedure
* high narcotis use greater than 30 mg hydrocodone or equivalent
* smokers
* body mass index greater than 29.9

Primary outcomes:
measure: Pain Status Change for Sacroiliac Joint Pain Intensity
timeFrame: Baseline and 3 months
Secondary outcomes:
Other outcomes:
measure: Pain Status Change for Sacroiliac Joint Pain Intensity
timeFrame: Baseline and 6 Months
measure: Pain Status Change for Sacroiliac Joint Pain Intensity
timeFrame: Baseline and 9 Months
Locations:
city: Bradenton
country: United States
facility: Coastal Orthopedics & Sports Medicine
state: Florida
Study officials:
affiliation: Coastal Orthopedics & Sports Medicine
name: Nileshkumar Patel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05514197: The Impact of Intravenous Vitamin C Combined With Nerve Blocks on Postoperative Pain and Recovery After Total Knee Arthroplasty
Official title: The Impact of Intravenous Vitamin C Combined With Nerve Blocks on Postoperative Pain and Recovery After Total Knee Arthroplasty.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ascorbic Acid
Postoperative Pain
Keywords: Ascorbic Acid
Total knee arthroplasty
Regional analgesia
Lead sponsor: Chimei Medical Center
Sponsor class: OTHER
First posted: 2022-08-24
Enrollment: 73
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this prospective randomized-control study was to evaluate the impact of a single high-dose intravenous vitamin C added to ultrasound-guided blocks at induction on postoperative pain, sngception and early functional rehabilitation of the knee joint in patients under-going total knee arthroplasty.


Eligibility criteria: Inclusion Criteria:

1. Physical status according to American Society of Anesthesiologists (ASA) I-III
2. Patients scheduled for total knee arthroplasty
3. Age ranging from 50 to 80 years old

Exclusion Criteria:

1. Previous operation on the same knee
2. Allergy or intolerance to one of the study medications
3. Coagulopathy
4. Having lower limbs neuropathy
5. End-organ failure (CKD stage V or VI, NYHA III or IV)
6. BMI \> 35
7. Chronic opioid use or drug abuser
8. Difficulty in communication (Impaired mental status)
9. Hyperuricemia or Glucose-6-phosphate dehydrogenase deficiency patient

Primary outcomes:
measure: Visual analogue scale for pain
timeFrame: 15 minutes postoperatively
measure: Visual analogue scale for pain
timeFrame: first hour postoperatively
measure: Visual analogue scale for pain
timeFrame: 6th hour postoperatively
measure: Visual analogue scale for pain
timeFrame: 24th hour postoperatively
measure: Visual analogue scale for pain
timeFrame: 48th hour postoperatively
Secondary outcomes:
measure: Visual analogue scale for sngcetion
timeFrame: 48 hours postoperatively
measure: Morphine consumption
timeFrame: 24 hours postoperatively
measure: Time to first rescue morphine requirement at post-anesthetic care unit
timeFrame: up to 2 hours
measure: Severity of postoperative nausea/ vomiting and dizziness
timeFrame: 48 hours postoperatively
Other outcomes:
measure: Blood ascorbic acid concentration
timeFrame: Preoperative baseline and postoperative day1
measure: PostOP Knee joint range of motion
timeFrame: 72 hours postoperatively
Locations:
city: Tainan
country: Taiwan
facility: Chi Mei Medical Center
state: Tainan City
Study officials:
affiliation: Department of Anesthesiology, Chimei Medical Center
name: Jen-Yin Chen
role: STUDY_DIRECTOR
References: